142 related articles for article (PubMed ID: 19021608)
1. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?
Schroeck FR; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2009 Mar; 103(5):603-8. PubMed ID: 19021608
[TBL] [Abstract][Full Text] [Related]
2. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group.
Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
Urology; 2013 Jul; 82(1):53-8. PubMed ID: 23806388
[TBL] [Abstract][Full Text] [Related]
3. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
4. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.
Schroeck FR; Kattan MW; Moul JW; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Sun L; Freedland SJ
BJU Int; 2010 Jun; 105(12):1654-9. PubMed ID: 19912203
[TBL] [Abstract][Full Text] [Related]
5. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
Int J Urol; 2010 Nov; 17(11):914-22. PubMed ID: 20880361
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
[TBL] [Abstract][Full Text] [Related]
7. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group.
Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2009 Dec; 104(11):1604-9. PubMed ID: 19549124
[TBL] [Abstract][Full Text] [Related]
8. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
[TBL] [Abstract][Full Text] [Related]
9. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
10. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
12. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):87-93. PubMed ID: 19918263
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.
Do Carmo Silva J; Vesely S; Luksanova H; Prusa R; Babjuk M
Tumour Biol; 2021; 43(1):197-207. PubMed ID: 34486998
[TBL] [Abstract][Full Text] [Related]
14. External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database.
Teeter AE; Sun L; Moul JW; Freedland SJ
BJU Int; 2010 Sep; 106(6):796-800. PubMed ID: 20151967
[TBL] [Abstract][Full Text] [Related]
15. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
16. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
17. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.
Laajala TD; Seikkula H; Seyednasrollah F; Mirtti T; Boström PJ; Elo LL
Sci Rep; 2016 Nov; 6():36161. PubMed ID: 27805011
[TBL] [Abstract][Full Text] [Related]
19. Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Branche BL; Howard LE; Hamilton RJ; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Kane CJ;
BJU Int; 2019 Jul; 124(1):69-75. PubMed ID: 30347135
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
